RxDoctor Payments Data

James Dunn, MD

Obstetrics & Gynecology · Auburn, CANPI 1093700528

Payments from drug & device makers

$8,480in general payments, 2019–2025

Across 308 payments — averaging $27.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • AbbVie$2K
  • Coloplast$1K
  • Astellas Pharma US Inc$549
  • Pfizer$521
  • Sumitomo Pharma America, Inc.$366
  • plus $2K from 27 others

What the payments were for

  • Travel & lodging$2,12425%
  • Food & beverage$6,23974%
  • Education$1171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,480 in reported general payments places this provider in the 90th percentile of 3,784 obstetrics & gynecology providers in California.

See all obstetrics & gynecology providers in California

Medicare billing

Part B allowed, 2024
$730,261
Medicare patients
920
Services billed
19,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron238$193,852
GemtesaVibegron176$146,492
Estradiol533$55,464
YuvafemEstradiol140$23,227
PremarinEstrogens, Conjugated41$16,201
ElmironPentosan Polysulfate Sodium14$12,581
EstringEstradiol14$7,587
ImvexxyEstradiol19$5,866
DottiEstradiol19$2,313
Estradiol (Once Weekly)Estradiol27$2,306
Vivelle-DotEstradiol12$1,615
Clobetasol Propionate38$1,559
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst41$1,253
ValacyclovirValacyclovir Hcl17$1,111
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip25$677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$549$193,852238 claims
Sumitomo Pharma America, Inc.Gemtesa$366$146,492176 claims
PfizerPremarin, Estring$521$23,78855 claims
Therapeuticsmd, Inc.Imvexxy$68$5,86619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,784 obstetrics & gynecology providers in California.

Other obstetrics & gynecology in Auburn

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →